CancerDrs Find care

Ovarian Cancer clinical trials

300 actively recruiting ovarian cancer trials in the United States. Epithelial ovarian cancer and related gynecologic malignancies. Trials focus on PARP inhibitors, immunotherapy, and maintenance strategies.

Data from ClinicalTrials.gov · last refreshed · Ovarian Cancer stats on SEER

79
Phase 1
107
Phase 2
16
Phase 3
1
Phase 4
97
Other

Ovarian Cancer by the numbers (U.S.)

20,890
Estimated new cases (2025)
12,730
Estimated deaths (2025)
51.6%
5-year relative survival
63
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse ovarian cancer trials by state

Texas 135 New York 107 California 104 Florida 90 Ohio 78 Pennsylvania 76 Massachusetts 70 Virginia 69 Michigan 63 Illinois 55 Minnesota 55 Tennessee 55 Maryland 50 North Carolina 50 Washington 48 Missouri 47 New Jersey 47 Colorado 41 Arizona 40 Oklahoma 40 Georgia 38 Oregon 35 Indiana 32 Connecticut 31 Utah 30 Wisconsin 29 Alabama 26 Kentucky 26 Rhode Island 22 South Carolina 21 Louisiana 20 Nebraska 20 Nevada 19 Arkansas 18 Iowa 17 South Dakota 16 Kansas 15 New Mexico 15 Maine 12 District of Columbia 11 Montana 11 North Dakota 11 West Virginia 10 Alaska 9 Hawaii 9 Mississippi 9 Delaware 8 Idaho 8 New Hampshire 8 Vermont 4 Wyoming 2

Top trials by phase + site coverage

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska

+ 1188 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska

+ 564 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 182 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whos…

Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • HonorHealth — Phoenix, Arizona
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center — Burbank, California

+ 78 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…

Sponsor: AbbVie
NCT ID: NCT05445778
Locations:
  • Usa Mitchell Cancer Institute /ID# 269661 — Mobile, Alabama
  • Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 — Phoenix, Arizona
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 — Irvine, California

+ 71 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Locations:
  • Alaska Women's Cancer Care — Anchorage, Alaska
  • Yale University School of Medicine — New Haven, Connecticut
  • Sylvester Comprehensive Cancer Center at Lennar — Coral Gables, Florida

+ 36 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Locations:
  • HonorHealth — Phoenix, Arizona
  • University of Arkansas — Little Rock, Arkansas
  • UCLA Health — Los Angeles, California

+ 35 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Locations:
  • The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
  • University of Arizona Cancer Center — Tucson, Arizona
  • City of Hope — Duarte, California

+ 28 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Locations:
  • University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
  • Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) — New Haven, Connecticut

+ 26 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Locations:
  • Scripps Clinic — La Jolla, California
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Jupiter Medical Center — Jupiter, Florida

+ 21 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Locations:
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Cleveland Clinic Foundation - Florida — Weston, Florida
  • Massachusetts General Hospital — Boston, Massachusetts

+ 10 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

A Study of Intra-operative Imaging in Women With Ovarian Cancer

The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04878094
Locations:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey

+ 6 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20